21098-11-3

Basic information

• Product Name: 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione
• Synonyms: 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione;Buspirone EP Impurity L
• CAS NO: 21098-11-3
• Molecular Formula: C₁₃H₂₀ClNO₂
• Molecular Weight: 257.7564
• Product Categories: Heterocycles, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 21098-11-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 429.4°C at 760 mmHg
• Flash Point: 213.5°C
• Appearance: /
• Density: 1.18g/cm³
• Vapor Pressure: 1.41E-07mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• PKA: -1.48±0.20(Predicted)
• CAS DataBase Reference: 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione(21098-11-3)
• EPA Substance Registry System: 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione(21098-11-3)

Safety Data

• Hazardous Substances Data: 21098-11-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 21098-11-3 differently. You can refer to the following data:
1. 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione is an impurity of Buspirone (B689850), an non-benzodiazepine anxiolytic; 5-hydroxytryptamine (5-HT1) receptor agonist.
2. 8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione (Buspirone EP Impurity L) is an impurity of Buspirone (B689850), an non-benzodiazepine anxiolytic; 5-hydroxytryptamine (5-HT1) receptor agonist.

InChI:InChI=1/C13H20ClNO2/c14-7-3-4-8-15-11(16)9-13(10-12(15)17)5-1-2-6-13/h1-10H2

Upstream product

• 6940-78-9 4-chlorobutyl bromide 
• 1075-89-4 tetramethylene glutarimide 

Downstream Products

• 80827-71-0 8-[4-(2-Methyl-4-[phenylmethyl]-1-piperazinyl)-butyl]-8-azaspiro[4.5]decane-7,9-dione 
• 87691-91-6 tiospirone 

Relevant articles and documents

Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect

In the present study, a series of multi-target N-substituted cyclic imide derivatives which possessed potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties were synthesized and evaluated as potential antipsychotics. Among these compounds, (3aR,4R,7S,7aS)-2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione hydrochloride (3d) held a promising pharmacological profile. 3d not only showed potent and balanced in vitro activities on D2/5-HT1A/5-HT2A receptors, but also endowed with low to moderate activities on 5-HT2C, H1, α1A, M3 receptors and hERG channel, suggesting a low liability to induce side effects such as weight gain, orthostatic hypotension and QT prolongation. In animal behavioral studies, 3d reduced phencyclidine-induced hyperlocomotion with a high threshold for catalepsy induction. Compound 3d was selected as a potential antipsychotic candidate for further development.

Polycyclic spiroimides with psychotropic activity

There are disclosed compounds of the formula STR1 wherein R1 and R2 taken together represent STR2 with the proviso that in STR3 when X is lower alkylene or O, m is other than 1; and when R1 and R2 taken together represent STR4 R3 is other than unsubstituted or substituted 2-pyridinyl or 2-pyrimidinyl; R3 is unsubstituted or substituted 2-pyridinyl, 2-pyrimidinyl, 2-pyrazinyl or 3-pyridazinyl, where the substituents are selected from the group lower alkyl, lower alkoxy, halo, cyano and nitro; Z is --(CH2)n -- or vinylene; X is lower alkylene, vinylene or O; m is 1-4; n is 1-3; o is 1-5; p is 0-1; and the pharmaceutically acceptable salts thereof and their use as antipsychotic/anxiolytic agents having a low liability for extrapyramidal side effects.